LUMCi029-A-2

IsoLUMC0072iENG p.Met1Val-F5

The cell line is not validated yet.

General

Cell Line

hPSCreg name LUMCi029-A-2
Cite as:
LUMCi029-A-2
Alternative name(s)
IsoLUMC0072iENG p.Met1Val-F5
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 14th October 2025
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Leiden University Medical Center (LUMC)
Owner Leiden University Medical Center (LUMC)
Distributors
Derivation country Netherlands

External Databases

BioSamples SAMEA120356029

General Information

* Is the cell line readily obtainable for third parties?
No
Subclone of

Donor Information

General Donor Information

Sex male
Ethnicity unknown

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Family history N/A
Is the medical history available upon request? No
Is clinical information available? No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA6673739

Ethics

Also have a look at the ethics information for the parental line LUMCi029-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? Yes
Constraints for use or distribution waste material, no inform consent

hIPSC Derivation

General

The source cell information can be found in the parental cell line LUMCi029-A.

Reprogramming method

Vector type Non-integrating
Vector RNA
Genes
Is reprogramming vector detectable?
Unknown

Vector free reprogramming

Other

Selection criteria for clones morphology
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Vitronectin
Feeder cells
No
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
O2 Concentration 20 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: StemFlex
Main protein source: StemFlex Supplement
Serum concentration: %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
Brachyury (TBXT)
Yes
Vimentin
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
FOXA2
Yes
GATA4
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
FABP7
Yes
Nestin
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
normal
Passage number: 29
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
Synonyms
  • HHT1
  • hereditary hemorrhagic telangiectasia type 1
  • telangiectasia, hereditary hemorrhagic, of Rendu, Osler, and Weber
  • telangiectasia, hereditary hemorrhagic, type 1
  • ENG-related Hereditary hemorrhagic telangiectasia
  • HHT
  • ORW disease
  • Osler Weber Rendu syndrome type 1
  • Osler-Rendu-Weber disease
  • telangiectasia, hereditary hemorrhagic, of RENDU, Osler, and WEBER
show more synonyms
Genetic modifications
Gene knock-out
9q34.11
c.1A>G p.Met1Val START codon
CRISPR-associated (CRISPR/Cas) System
Genetic modifications not related to a disease
Variant
9q34.11
Homozygous
A silent mutation, ENG c.10G>C, was introduced downstream of the disrupted start codon to eliminate the PAM sequence and facilitate screening with a restriction enzyme.